Insights on geroscience pre-clinical and clinical trials to promote healthy aging from the Intrinsic Capacity, Frailty and Sarcopenia Research Task Force 2025 - PubMed
6 hours ago
- #geroscience
- #clinical trials
- #healthy aging
- The Intrinsic Capacity, Frailty and Sarcopenia Research (ICFSR) Task Force discussed geroscience-oriented pre-clinical and clinical trials for healthy aging in March 2025.
- Key topics included aging biomarkers, senotherapeutics, metabolism-targeting medications, and non-pharmacological therapeutic strategies.
- Challenges identified include deeper understanding of aging biology, validation of aging biomarkers against clinical outcomes like frailty, and enhancing clinical trial methodologies.
- There is a need for harmonization in geroscience studies, such as defining a minimum common dataset of biological, physiological, and clinical factors.
- A paradigm shift among regulatory authorities is necessary to accelerate innovation in the field.
- Several task force members have affiliations or financial interests with industrial partners in the geroscience field.